BACKGROUND
Anthracycline-free TCHP and anthracycline-based AC-THP are both used as neoadjuvant dual anti-HER2 regimens for HER2-positive breast cancer, but direct comparisons accounting for HER2 immunohistochemistry (IHC) intensity are lacking. Because IHC 3+ tumors respond substantially better to dual blockade, any be...
B. Sharaf, F. Tamimi, Mohammad Alzoubi et al.· Cancer Treatment and Researc...· 0 citations
The findings provide real-world historical outcome data for patients who would now be considered candidates for adjuvant ribociclib and may serve as a benchmark for evaluating outcomes following adoption of adjuvant ribociclib.
H. Abdel-Razeq, M. Horani, F. Tamimi et al.· Drug Design, Development and...· 0 citations
A narrative review of emerging cancer treatment data, molecular profiling technologies, and existing clinicogenomic databases, focusing on how tumors are characterized, how subgroups are defined, and how demographic, lifestyle, and environmental factors are captured.
Farhood Farahnak, W. El-Deiry, Yves A. Lussier et al.· JCO Global Oncology· 0 citations
Germline P/LP variants are common in young male patients with cancer, particularly at younger ages and among those meeting testing criteria, and these findings support broader implementation of germline testing to inform management and familial risk assessment.
H. Abdel-Razeq, Hira Bani Hani, Seif Alafeef et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.